Akebia Therapeutics

CEO John P. Butler has deep renal market experience (ex‑Genzyme renal lead) and has navigated FDA reversal to approval, dialysis access build‑out, and portfolio expansion. The company strengthened the bench in 2024–2026 with a new CFO (Erik Ostrowski) and added R&D leadership and a nephrology‑savvy board member (Philip Vickers).

Execution on protocol access and post‑marketing evidence generation is visible, but financing reliance and a need to refinance by 2027 temper the assessment.